Outlook Therapeutics Inc | Needs refresh | Last updated: 2026-04-23T10:26:17Z
Outlook Therapeutics Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for Factor IX (rFIXFc) in Severe Hemophilia B (Phase 3).
| Asset | Indication | Modality | Stage | Public Note |
|---|---|---|---|---|
| ONS-5010 | n/a | n/a | n/a | Public pipeline row |
| ABOUT ONS-5010 | n/a | Monoclonal Antibody | n/a | Public pipeline row |
| Positive Action | Character | Violence | Substance Use | Pro-social Behavior | Academic Achievement | n/a | Na | Public pipeline row |
| Behavioural Counselling | Cancer | Exercise | n/a | Na | Public pipeline row |
| Behavioral Health Home Hospital | Psychosis | Anxiety | Depression | Behavioral and Psychiatric Symptoms of Dementia | n/a | Na | Public pipeline row |
| Phenylephrine | Adverse Effect | n/a | Na | Public pipeline row |
| Adjusted Content Intervention | Stigma, Social | Help-Seeking Behavior | n/a | Na | Public pipeline row |
| Non-interventional Study | n/a | n/a | n/a | Public pipeline row |
Estimated cash runway: Runway < 6 months.
This is an automated estimate and may differ from company guidance.
| NCT ID | Phase | Status | Enrollment | Primary Completion |
|---|---|---|---|---|
| NCT00328445 | Na | COMPLETED | 2500 | 2006-06 |
| NCT01027364 | Phase 3 | COMPLETED | 123 | 2012-07 |
| NCT01565980 | Na | COMPLETED | 40 | 2013-06 |
| NCT02341664 | n/a | COMPLETED | 7658 | 2016-02 |
| NCT04556357 | Na | COMPLETED | 138 | 2021-11-15 |
| NCT05826132 | Na | COMPLETED | 1402 | 2024-01-31 |
| NCT03527472 | Phase 2 | ACTIVE_NOT_RECRUITING | 111 | 2026-02-28 |
| NCT07364825 | Na | RECRUITING | 45 | 2026-04-30 |
Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.
Get the weekly biotech catalyst watchlistThis page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.